In short
ITI-1284 is an investigational drug being studied in various clinical trials for its potential in treating conditions such as agitation and psychosis associated with Alzheimer's dementia, as well as generalized anxiety disorder. These trials aim to assess the drug's efficacy, safety, and tolerability in different patient populations. Additionally, studies are being conducted to understand the drug's pharmacokinetics and its interaction with brain receptors in healthy volunteers.
At a glance
- Drug Name
- ITI-1284
- Conditions Studied
- Agitation in Alzheimer's Dementia, Psychosis in Alzheimer's Disease, Generalized Anxiety Disorder
- Administration
- Sublingual, once daily
- Doses Tested
- 10 mg and 20 mg
- Study Designs
- Randomized, double-blind, placebo-controlled
- Treatment Duration
- 6-12 weeks
- Primary Outcome Measures
- CMAI, BEHAVE-AD psychosis subscale, HAM-A
- Secondary Outcome Measures
- CGI-S, adverse events, vital signs, laboratory tests
- Additional Studies
- Mass balance, brain receptor occupancy, pharmacokinetics in healthy volunteers
What is ITI-1284?
ITI-1284 is a new medication currently being studied for its potential to treat various mental health conditions. It is undergoing clinical trials to evaluate its effectiveness, safety, and how well patients tolerate it. The drug is being tested in different dosages, typically 10 mg and 20 mg.
How is ITI-1284 Administered?
ITI-1284 is administered as a sublingual tablet. This means the tablet is placed under the tongue, where it quickly dissolves. It is typically taken once daily. Some studies describe ITI-1284 as a rapidly disintegrating tablet, which suggests it dissolves quickly in the mouth.
Conditions Treated by ITI-1284
ITI-1284 is being studied for several mental health conditions:
- Generalized Anxiety Disorder (GAD): This is a condition characterized by persistent and excessive worry about various aspects of life.
- Agitation Associated with Alzheimer's Dementia: This refers to restlessness, emotional distress, or aggressive behavior that can occur in people with Alzheimer's disease.
- Psychosis Associated with Alzheimer's Disease: This involves experiencing hallucinations (seeing or hearing things that aren't there) or delusions (false beliefs) in people with Alzheimer's disease.
Ongoing Clinical Trials
Several clinical trials are currently underway to study ITI-1284:
- PET Study in Healthy Volunteers: This study aims to understand how ITI-1284 interacts with dopamine D2 receptors in the brain. It also looks at the drug's safety and how it moves through the body (pharmacokinetics).
- Generalized Anxiety Disorder (GAD) Studies: Two separate studies are examining ITI-1284 for GAD:
- One study is testing ITI-1284 as a standalone treatment (monotherapy) for GAD.
- Another study is evaluating ITI-1284 as an additional treatment (adjunctive therapy) for patients who haven't responded well to other GAD treatments.
- Alzheimer's Disease Studies: Two studies are focusing on symptoms associated with Alzheimer's disease:
- One study is investigating ITI-1284 for treating agitation in Alzheimer's patients.
- Another study is examining ITI-1284's effectiveness in treating psychosis in Alzheimer's patients.
Safety and Side Effects
While the full safety profile of ITI-1284 is still being studied, the clinical trials are monitoring several aspects of safety:
- Treatment-emergent adverse events: These are any unfavorable and unintended signs, symptoms, or diseases that occur during the treatment period.
- Changes in ECG QT interval: This is a measure of the heart's electrical activity and can indicate potential heart-related side effects.
- Changes in liver enzymes: Specifically, aspartate aminotransferase and alanine aminotransferase are being monitored, which can indicate potential effects on liver function.
It's important to note that all medications can have side effects, and the full range of potential side effects for ITI-1284 will become clearer as more research is conducted.
Measuring Effectiveness
The clinical trials are using several standardized scales to measure how well ITI-1284 works:
- Hamilton Anxiety Rating Scale (HAM-A): This scale measures both psychological and physical symptoms of anxiety. It includes 14 items rated from 0 (not present) to 4 (very severe). A higher score indicates more severe anxiety.
- Clinical Global Impression Scale-Severity (CGI-S): This scale assesses a patient's overall mental health. It ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).
- Cohen-Mansfield Agitation Inventory (CMAI): This scale is used to assess agitated behavior in elderly patients. It includes 29 items, each rated on a 7-point scale of frequency.
- BEHAVE-AD psychosis subscale: This scale is used to measure psychotic symptoms in Alzheimer's disease patients. It includes items related to paranoid and delusional ideations, as well as hallucinations.
These scales help researchers determine if ITI-1284 is effectively reducing symptoms of the conditions it's being tested to treat.